Inhibrx takes a second shot at an IPO — this time bumping the goal to $100M-plus
La Jolla, CA-based Inhibrx couldn’t get their $75 million IPO over the goal line last year. But with the fervor for new biotech filings seemingly growing on Wall Street, they plan to see how a $100 million play will work out now.
This time around, Inhibrx touts four Phase I drugs in the pipeline developed on its single domain antibody (sdAb) platform, three of which are geared toward various cancers. The fourth drug, INBRX-101, targets Alpha-1 Antitrypsin Deficiency (AATD).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
